CEL SCI CORP

CEL SCI CORP's capital structure is marked by a high debt-to-equity ratio of 0.83 and a current ratio of 0.6, indicating that current liabilities exceed current assets. The company's liquidity position is further strained by a negative operating cash flow of -$8,044,494 and a free cash flow of the same amount, with no capital expenditures recorded. The price-to-book ratio of 1.91 suggests that the market value is somewhat higher than the book value, but the negative return on equity of -1.59 and return on assets of -0.62 highlight poor profitability. Profitability metrics for CEL SCI CORP are significantly below industry norms, with a negative net income of -$10,935,197 and an operating income of -$10,694,815. The company's return on equity and return on assets are also negative, indicating that it is not generating returns on its equity or assets. These figures suggest that the company is struggling to convert its investments into profits, which is a concern for investors. The company's revenue is primarily concentrated in the United States, with no significant geographic diversification reported. The lack of geographic diversification increases the company's exposure to local market conditions and regulatory changes. Additionally, the company's reliance on a single product candidate, Multikine, for its future growth is a significant risk. The growth trajectory of CEL SCI CORP is uncertain, with a net decrease in cash and cash equivalents of $9,062,728 in the six months ended March 31, 2026. The company's liquidity position is further exacerbated by the substantial doubt about its ability to continue as a going concern, as noted in its filings. The company's future financial performance is contingent on the success of its clinical trials and the potential approval of Multikine. The risk assessment for CEL SCI CORP indicates a high liquidity risk and a medium dilution risk. The company's filings reference going-concern or substantial-doubt language, and there are mentions of dilution or offering risk. The company's debt-to-equity ratio of 0.83 and the negative operating cash flow contribute to the liquidity risk. The dilution risk is further compounded by the company's need to raise additional capital to fund its operations. Recent events, as detailed in the company's filings, include a net loss of $10,935,197 and a net cash used in operating activities of $8,044,494. The company has also recognized an impairment loss on its patents, which is a concern for its asset valuation. The company's ability to continue as a going concern is in doubt due to recurring losses and future liquidity needs. The company has expanded its manufacturing facility to meet potential demand for Multikine if approved.